Weekly company factor report
NATCOPHARM Valuation, Quality and Momentum
NATCO Pharma Limited
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
The completed price record is weak and does not support the other measures yet.
Value supported by price performance
The value rank is 76/100 and the price-performance rank is 70/100. Both measures are above most companies in the selected market.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for NATCOPHARM.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Value measures compared
Raw multiples and yields
P/E history
P/E is shown only when trailing earnings are positive.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Current reading
Conservative balance sheet with D/E of 0.20.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
Near-term vol (77%) is expanding vs long-term (32%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.890 | Unchanged for 17 snapshots | deteriorating |
| Value %ile | 0.760 | Unchanged for 17 snapshots | deteriorating |
| Quality %ile | 0.640 | Unchanged for 0 snapshots | deteriorating |
| Momentum %ile | 0.700 | Unchanged for 1 snapshots | stable |
| F-Score | 4.000 | Unchanged for 17 snapshots | stable |
| Confidence | 0.909 | Unchanged for 17 snapshots | improving |
| Volatility | 0.319 | Unchanged for 0 snapshots | deteriorating |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| SPARC Sun Pharma Advanced Research Company Limited | 98.0 | 81.0 | 98.0 | 91.0 |
| LUPIN Lupin Limited | 96.0 | 76.0 | 99.0 | 75.0 |
| VENUSREM Venus Remedies Limited | 96.0 | 69.0 | 90.0 | 99.0 |
| AUROPHARMA Aurobindo Pharma Limited | 95.0 | 70.0 | 82.0 | 91.0 |
| LINCOLN Lincoln Pharmaceuticals Limited | 95.0 | 86.0 | 71.0 | 75.0 |
| STAR Strides Pharma Science Limited | 94.0 | 68.0 | 89.0 | 86.0 |
| SAGILITY Sagility Limited | 93.0 | 71.0 | 88.0 | 72.0 |
| ANUHPHR Anuh Pharma Limited | 89.0 | 76.0 | 63.0 | 72.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Net margin
Operating income
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 25 Sep 2026
Company and valuation evidence are ahead of the price record
The company and valuation checks pass; completed price support is still building.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 72/100 Checks profitability, cash support, balance-sheet measures and their direction.
- ✓ Relative valuePassed · 76/100 Checks whether the current valuation compares well with the selected market.
- 4 Market supportNeeds more evidence · 50/100 Checks completed price performance, relative strength, trend and buying pressure.
- 5 Setup and riskNot reached · 29/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewNot reached Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 64/100
- F-Score 4/9
- 4 usable annual periods
- Value rank 76/100
- P/E 13.4×
- Free-cash-flow yield Not available
- Price-performance rank 70/100
- Six-month return -14.2%
- Relative strength +0.1
- Stage 4 · Declining
- Stage 4 · Declining
- Price at -30.0% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 31.9%
- Recent volatility 76.6%
- 12-month drawdown -32.2%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 72/100.
- Relative value scores 76/100.
What still needs attention
- Market support scores 50/100.
- Setup scores 29/100.
- Risk check scores 40/100.
Next check
Wait for broader completed price, trend and relative-strength confirmation.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for NATCOPHARM are shown.